Despite initial dramatic efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant lung cancer patients, subsequent emergence of acquired resistance is almost inevitable. Resveratrol and its derivatives have been found to exert some effects on EGFR-TKI resistance in non-small cell lung cancer (NSCLC), but the underlying mechanisms remain unclear. We screened 
study of targeting the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has become a hot spot in NSCLC treatment. [2] [3] [4] [5] That is, by competitively binding extracellular ligand binding sites with ATP or other substrates, blocking EGFR tyrosine autophosphorylation and tyrosine kinase activation, leading to EGFR activation inhibition and downstream signal transduction disorder, ultimately inhibiting cell cycle progression, accelerating apoptosis, disrupting angiogenesis, invasion and metastasis. 2, 3 Gefitinib is a commonly used EGFR-TKI drug for NSCLC treatment. EGFR-TKIs can prolong patients' progression free survival and overall survival in NSCLC clinical treatment, especially in relatively sensitive patients, both in one-line and multi-line treatment and the side effects are mild. 4 However, there is no significant effect of EGFR-TKs on some patients, EGFR mutations for example; or patients initially sensitive
to EGFR-TKIs with good efficacy for some time (about 1-1.5 years), but subsequently prone to develop disease progression and EGFR-TKI resistance, the so-called secondary resistance. 5 Trans-3,5,4′-trimethoxystilbene (TMS), a polyphenolic compound known by the chemical name of Stilbene, is a synthetic analogues of resveratrol, a constituent of red wine, vegetables and Chinese medicines, Polygonum cuspidatum for example. 6 TMS has been reported to possess more potent anticancer and antiangiogenic activities than resveratrol. [7] [8] [9] [10] Resveratrol and its derivatives have been found to exert some effects on NSCLC, 11 especially on EGFR-TKI resistance, but the underlying mechanisms remain unclear.
MiRNAs are a group of non-coding small RNAs about [22] [23] [24] [25] [26] nucleotides, involved in the regulation of gene expression at the posttranscriptional level. In recent years, miRNAs have become the focus of oncology research. Although only about 1% of human genes, miRNAs regulate about 30% of the human-encoded protein genes involved in the occurrence and development of many tumours, including lung cancer. 12, 13 Recent research found that miRNAs involved in a variety of tumour drug resistance, especially in NSCLC, can affect the chemosensitivity of gefitinib and other drugs involved in EGFR-TKIs resistance. 14, 15 MiR-345 and miR-498 were found to be downregulated in NSCLC patients and cell lines and closely associated with the tumour progression and poor prognosis, 16, 17 but there were few reports about the molecular regulation mechanism of miR-345 and miR-498 in NSCLC, especially in the EGFR-TKI resistance.
In this study, we have identified a remarkable sensitization to 
| MATERIALS AND METHODS

| Cell culture and drug treatment
The human NSCLC cell lines PC-9, H1975, A549, H1299 and PC-9/ GR were obtained from ATCC (US) and cultured in RPMI1640 medium supplemented with 10% v/v FBS (Gibco, USA) in a humidified atmosphere of 95% air and 5% CO 2 . To screen the gefitinib resistant cell strains, a dose gradient (0, 5, 10, 50, 100, 200, 500 μmol/L) of gefitinib (Sigma, USA) was administered for 48 hours.
The gefitinib-acquired resistant cell subline PC-9/GR was established by chronic exposure of PC-9 cells to medium with increasing concentrations of gefitinib as described previously. 18 To confirm the best fit for TMS (Sigma) treatment, a certain concentration range (0, 0.5, 5, 50, 500 μmol/L) was administered for 24, 48 or 72 hours.
After treatment with TMS and/or gefitinib, cells were collected for analysis. 
| MiRNA transfection
| Flow cytometric analysis
The apoptosis analysis was performed with a fluorescein isothio- 
| Immunoblotting analysis
Protein samples were prepared using M-PER (Thermo Scientific, were given every 4 days and for four times in total. Each treatment group consisted of at least five mice. Tumour volume was calculated using the formula π/6 × larger diameter × (smaller diameter) 2 as described previously. 19 About a month later after administration, all the mice were killed and the tumour samples were collected for further analysis and detection.
| Statistical analysis
Data are indicated as mean ± SD for at least three different determinations. Statistical analysis was performed with the SPSS software (Chicago, IL, USA). Differences between variants were analysed by the Student's t test or one-way ANOVA. Date were regarded as statistically significant when P value was at least less than 0.05. All data was illustrated as mean ± SD and the asterisks show significant difference as *P < 0.05, **P < 0.01, ***P < 0.001 compared with the miR-NC group or between the two groups shown by a horizontal line ( Figure 3A ) and PC-9/GR and cell growth curve and cell cycle were analysed by MTT assay and flow cytometry. Results displayed that miR-345 and miR-498 overexpression inhibited H1299 and PC-9/GR cell proliferation ( Figure 3B ) and induced cell cycle arrestin G1/G0 phage ( Figure 3C ) compared with blank control and miR-NC groups.
In order to further confirm whether it was the upregulation of miR-345 and miR-498 by TMS to promote cell apoptosis, miRNA inhibitors were used to antagonize miR-345/miR-498 and flow cytometry analysis was performed. As shown in Figure 3D , inhibition of miR-345 or miR-498 weakened the effect of TMS and restored cellular resistance to gefitinib by decreasing apoptosis.
| MiR-345 and miR-498 regulated the MAPK/cFos and Akt/Bcl-2 pathways by targeting MAPK1 and PIK3R1 respectively
Software prediction by TargetScan, DIANA Tools and miRDB found MAPK1, a vital member of MAPK family, is a target of miR-345 and PIK3R1, an essential component of the PI3K/Akt signalling pathway, is a target of miR-498. 21 The potential interaction sites of miRNA and the 3′-UTR of its target genes were analysed using the RNAhybrid 2.2 software and mutations were introduced into these sites (in bold) to create an miRNA insensitive 3′-UTR ( Figure 4A ). The dualluciferase reporter assays displayed that miR-345 inhibited the luciferase activity with wild-type MAPK1-3′-UTR (MAPK1-WT) but had no significant effect on the luciferase activity with mutant MAPK1-3′-UTR (MAPK1-MUT). Inhibition of miR-345 enhanced the luciferase activity with wild-type MAPK1-3′-UTR ( Figure 4B ). As expectedly, similar findings were also obtained on the interaction of miR-498 between with the wild-type PIK3R1-3'UTR (PIK3R1-WT) or the mutant PIK3R1-3'UTR (PIK3R1-MUT) ( Figure 4C ). The effects on expression of targets by miRNA were also verified at the transcription and protein levels. As shown in Figure 4D ,E, miR-345 and miR-498 downregulated their targets expression both at mRNA and protein levels, while inhibition of miR-345 or miR-498 conversely upregulated these targets. MiR-345 and miR-498 also regulated the Recent studies have indicated that, the PC-9/GR cell subline achieves acquired resistance (AR) through the development of EMT. So, the expression of EMT markers after TMS treatment was analysed. Data indicated that TMS treatment significantly reduced EMT by upregulating E-cadherin and downregulating vimentin and N-cadherin in PC-9/GR cells, but these effects were reversed by the overexpression of MAPK1 or PIK3R1 suggesting that the gefitinib-AR of PC-9/ GR cells was reduced. However, these effects were relatively less dramatic in H1299 cells because of the weaker EMT in H1299 cells compared to PC-9/GR cells ( Figure 5F ). All these results suggested that TMS overcame gefitinib resistance in H1299 and PC-9/GR cells by inhibiting the MAPK/c-Fos and Akt/Bcl-2 signalling pathways.
3.6 | TMS enhanced gefitinib chemosensitivity on tumour growth inhibition by suppressing the MAPK/ Akt/Bcl-2 pathway through miR-345 and miR-498
As described above, gefitinib and TMS significantly inhibited in tumour growth ( Figure 2D ,E) and the upregulation of miR-345 and miR-498 may be the cause ( Figure 2F ). For further verification, antagomir-345 and antagomir-498 were used to block their upregulation and the results revealed that the tumour growth inhibition of gefitinib/TMS was abolished by antagomir-345 and antagomir-498, and the tumour volume and weight increased in the antagomir-345/ antagomir-498 groups compared to the antagomir-NC group (Figure 6A,B) . Similarly, the expression levels of the targets and downstream signalling molecules of miR-345 and miR-498 were also increased because of derepression by reduced miR-345 and miR-498 expression ( Figure 6C ). These findings further demonstrated in vivo that TMS enhanced the chemosensitivity of gefitinib on tumour growth inhibition by suppressing the MAPK/Akt/Bcl-2 pathway through miR-345 and miR-498.
| DISCUSSION
Gefitinib is a commonly used EGFR-TKI drug for NSCLC treatment, with characteristics of strong specificity, good tolerance and few adverse reactions. However, acquired drug resistance is the main reason for the failure of clinical gefitinib treatment becoming an urgent problem to NSCLC therapy and study. Resveratrol, a natural polyphenols has been reported to possess anticancer properties in a wide variety of tumour cell types including breast, prostate, stomach, colon, pancreas and thyroid cancers. 20, 21 It can suppress proliferation, invasion and apoptosis by regulating NF-κB and activator protein-1 activities. 18, 19 One of the resveratrol derivatives TMS was found to be more potent than resveratrol as an anticancer agent. 9, 11 In this study, we evaluated the anticancer effects in vitro and in vivo. To uncover the underlying molecular mechanisms of TMS, we also studied the cell cycle and gene expres- The PC-9/GR cell is a gefitinib-acquired resistant cell subline of PC-9 cells, which has an EGFR-activating mutation, which is a 15-bp deletion in the EGFR exon 19 and is initially sensitive to gefitinib. 18 The gefitinib resistance mechanism is very complex, may relate to secondary mutation of EGFR, c-Met amplification, compensatory signal establishment and the change in regulatory factors expression and the tumour microenvironment transformation.
Cheng et al detected that there was a T790M mutation which may be the cause of gefitinib-AR for PC-9/GR cells, although it occurs less frequently. 18 Recent studies have also indicated that there was not a T790M mutation in the PC-9/GR cell subline; however, it achieved AR through development of EMT. The expression of Ecadherin decreased but vimentin and N-cadherin increased in PC-9/ GR cells compared to the PC-9 cells indicating that PC-9/GR cells acquired the EMT phenotype. 31 As we know, MAPK and PI3K signalling pathways are involved in inducing tumour EMT and play roles in drug resistance. 32, 33 In our study, we have verified that TMS increased the sensitivity to gefitinib by reduced EMT by upregulating E-cadherin and downregulating vimentin and Ncadherin in PC-9/GR cells after suppressing MAPK and PI3K/AKT signalling pathways by upregulating miR-345/miR-498. But these effects were reversed by the overexpression of MAPK1 or PIK3R1, further suggesting that the gefitinib-AR of PC-9/GR cells was reduced by TMS. However, these effects were relatively less dramatic in H1299 cells because of the weaker EMT in H1299 cells, which were primarily resistant to gefitinib caused by TP53 deficiency and NRAS mutation. 34 In conclusion, we have demonstrated that the resveratrol derivative TMS could reduce gefitinib resistance in NSCLC cells and xenograft tumour tissues by blocking the PI3K/Akt and MAPK pathways by upregulating miR-345 and 498. Our data would lay the theoretical basis for the future study of TMS for the treatment of EGFR-TKI resistance in NSCLCs.
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